PMID- 25706572
OWN - NLM
STAT- MEDLINE
DCOM- 20160209
LR  - 20191113
IS  - 2291-2797 (Electronic)
IS  - 2291-2789 (Print)
IS  - 2291-2789 (Linking)
VI  - 29
IP  - 1
DP  - 2015 Jan-Feb
TI  - A study investigating the association of dermatological and infusion reactions to 
      infliximab and infliximab trough levels.
PG  - 35-40
AB  - BACKGROUND: Although infliximab is an effective therapy for inflammatory bowel 
      disease (IBD), it is associated with dermatological events and infusion 
      reactions. It is not known whether a relationship between these adverse events 
      (AEs) and infliximab trough levels (ITLs) exists. OBJECTIVES: To report the 
      prevalence of infliximab-associated AEs in IBD patients receiving stable 
      maintenance infliximab therapy, and to correlate ITLs with dermatological and 
      infusion reactions to infliximab. METHODS: Adult IBD patients receiving stable 
      maintenance infliximab therapy were recruited from the University of Alberta 
      Infusion Clinic (Edmonton, Alberta). ITLs were measured in blood samples 
      collected before infusion, and the patients' records were reviewed for 
      dermatological and infusion reactions to infliximab. RESULTS: One-quarter (18 of 
      71 [25.4%]) of patients experienced dermatological or infusion reactions to 
      infliximab: nine (12.7%) dermatological events and nine (12.7%) infusion 
      reactions. The median ITL was similar among patients with and without these AEs 
      (7.2 mug⁄mL [interquartile range (IQR) 2.0 mug⁄mL to 13.3 mug⁄mL] versus 6.6 mug⁄mL 
      [IQR 3.2 mug⁄mL to 12.7 mug⁄mL]; P=0.648). The median ITL of patients who 
      experienced infusion reactions (2.0 mug⁄mL [IQR 0.1 mug⁄mL to 5.7 mug⁄mL]) was lower 
      than that of patients who experienced no such AEs (6.6 mug⁄mL [IQR 3.2 mug⁄mL to 
      12.7 mug⁄mL]; P=0.008]) and lower than that of patients who experienced 
      dermatological AEs (13.3 mug⁄mL [IQR 8.8 mug⁄mL to 17.4 mug⁄mL]; P<0.001). 
      CONCLUSION: One-quarter of IBD outpatients receiving stable maintenance 
      infliximab therapy experienced dermatological and infusion reactions. Low ITLs 
      were correlated with infusion reactions, and normal or high ITLs with 
      dermatological events.
FAU - Huang, Vivian
AU  - Huang V
FAU - Dhami, Neil
AU  - Dhami N
FAU - Fedorak, Darryl
AU  - Fedorak D
FAU - Prosser, Connie
AU  - Prosser C
FAU - Shalapay, Carol
AU  - Shalapay C
FAU - Kroeker, Karen I
AU  - Kroeker KI
FAU - Halloran, Brendan P
AU  - Halloran BP
FAU - Dieleman, Levinus A
AU  - Dieleman LA
FAU - Fedorak, Richard N
AU  - Fedorak RN
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Egypt
TA  - Can J Gastroenterol Hepatol
JT  - Canadian journal of gastroenterology & hepatology
JID - 101623613
RN  - 0 (Gastrointestinal Agents)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Adult
MH  - Colitis, Ulcerative/drug therapy
MH  - Crohn Disease/drug therapy
MH  - Cross-Sectional Studies
MH  - Drug Eruptions/*blood
MH  - Drug Monitoring
MH  - Female
MH  - Gastrointestinal Agents/*adverse effects/*blood
MH  - Humans
MH  - Infliximab/*adverse effects/*blood
MH  - Infusions, Intravenous/adverse effects
MH  - Maintenance Chemotherapy/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
PMC - PMC4334065
EDAT- 2015/02/24 06:00
MHDA- 2016/02/10 06:00
PMCR- 2015/07/01
CRDT- 2015/02/24 06:00
PHST- 2015/02/24 06:00 [entrez]
PHST- 2015/02/24 06:00 [pubmed]
PHST- 2016/02/10 06:00 [medline]
PHST- 2015/07/01 00:00 [pmc-release]
AID - cjgh-29-35 [pii]
AID - 10.1155/2015/428702 [doi]
PST - ppublish
SO  - Can J Gastroenterol Hepatol. 2015 Jan-Feb;29(1):35-40. doi: 10.1155/2015/428702.